Novel monocyclam derivatives as HIV entry inhibitors: Design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor

ChemMedChem

Volumn 5, Issue 8, 2010, Pages 1272-1281

  Pettersson, Sofia ^a   Pérez Nueno, Violeta I ^a   Mena, Maria Pau ^b   Clotet, Bonaventura ^b   Esté, José A ^b   Borrell, José I ^a   Teixidó, Jordi ^a,c  

^a INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Edifici TecnoCampus v 10   (Spain)

Author keywords

CXCR4 antagonists; Docking; HIV 1 infection; Medicinal chemistry; Molecular dynamics

Indexed keywords

1 [4 (3 (2 METHYLPIPERIDIN 1 YL) PROPYL 1 AMINOMETHYL) PHENYLMETHYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE; 1 [4 (3 MORPHOLINOPROPYL 1 AMINOMETHYL) PHENYLMETHYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; AMD3451; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MONOCYCLAM DERIVATIVE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIMULATION; SITE DIRECTED MUTAGENESIS; VIRUS STRAIN;

CELL LINE; DRUG DESIGN; HETEROCYCLIC COMPOUNDS; HIV; HIV FUSION INHIBITORS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; RECEPTORS, CXCR4;

EID: 77955108676     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201000124     Document Type: Article

References (54)

1. UNAIDS, AIDS Epidemic Update: December 2007, http://www.unaids. org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default. asp (accessed May 11, 2010).
2. J. A. Esté, A. Telenti, Lancet 2007, 370, 81-88.
3. N. J. Anthony, Curr. Top. Med. Chem. 2004, 4, 979-990.
4. I. Markovic, K. A. Clouse, Curr. HIV Res. 2004, 2, 223-234.
5. J. A. Esté, T. Cihlar, Antiviral Res. 2010, 85, 25-33.
6. E. De Clercq, Med. Chem. Res. 2004, 14, 439-478.
7. E. De Clercq, Expert Opin. Emerging Drugs 2005, 10, 241-274.
8. W. M. Kazmierski, J. P. Peckman, M. Duan, T. P. Kenakin, S. Jenkinson, K. S. Gudmundsson, S. C. Piscitelli, P. L. Feldman, Curr. Med. Chem. Anti- Cancer Agents 2005, 4, 133-152.
9. K. de Vresse, D. Reymen, P. Griffin, A. Stinkasserer, G. Werner, G. J. Bridger, J. A. Esté, W. James, G. W. Henson, J. Desmyter, J. Anne, E. De Clercq, Antiviral Res. 1996, 29, 209-219.
10. D. Schols, J. A. Esté, G. Henson, E. De Clercq, Antiviral Res. 1997, 35, 147-156.
11. E. De Clercq, Mol. Pharmacol. 2000, 57, 833-839.
12. J. A. Esté, C. Cabrera, E. De Clercq, S. Struyf, J. van Damme, G. Bridger, R. T. Skerlj, M. J. Abrams, G. Henson, A. Gutiérrez, B. Clotet, D. Schols, Mol. Pharmacol. 1999, 55, 67-73.
13. S. Hatse, K. Princen, E. De Clercq, M. M. Rosenkilde, T. W. Schwartz, P. E. Hernandez-Abad, R. T. Skerlj, G. J. Bridger, D. Schols, Biochem. Pharmacol. 2005, 70, 752-761.
14. K. Princen, S. Hatse, K. Vermiere, S. Aquaro, E. De Clercq, L.-O. Gerlach, M. Rosenkilde, T. W. Schwartz, R. Skerlj, G. Bridger, D. Schols, J. Virol. 2004, 78, 12996-13006.
15. N. D. Stone, S. B. Dunaway, C. Flexner, C. Tierney, G. B. Calandra, S. Becker, Y.-J. Cao, I. P. Wiggins, J. Conley, R. T. MacFarland, J.-G. Park, C. Lalama, S. Snyder, B. Kallungal, K. L. Klingman, C. W. Hendrix, Antimicrob. Agents Chemother. 2007, 51, 2351-2358.
16. M. M. Rosenkilde, L.-O. Gerlach, S. Hatse, R. T. Skerlj, D. Schols, G. J. Bridger, T. W. Schwartz, J. Biol. Chem. 2007, 282, 27354-27365.
17. S. Pettersson, V. I. Pérez-Nueno, L. Ros-Blanco, R. Puig de La Bellacasa, M. O. Rabal, X. Batllori, B. Clotet, I. Clotet-Codina, M. Armand-Ugón, J. A. Esté, J. I. Borrell, J. Teixidó, ChemMedChem 2008, 3, 1549-1557.
18. V. I. Pérez-Nueno, S. Pettersson, D. W. Ritchie, J. I. Borrell, J. Teixidó, J. Chem. Inf. Model. 2009, 49, 810-823.
19. J. I. Luengo, A. T. Price, A. Shaw, K. Wiggall, World Patent WO 00/66112 (filing date: May 3, 2000).
20. C. Schickaneder, F. W. Heinemann, R. Alsfasser, Eur. J. Inorg. Chem. 2006, 2357-2363.
21. E. Kawabata, K. Kikuchi, Y. Urano, H. Kojima, A. Odani, T. Nagano, J. Am. Chem. Soc. 2005, 127, 818-819.
22. L.-O. Gerlach, R. Skerlj, G. Bridger, T. W. Schwartz, J. Biol. Chem. 2001, 276, 14153-14160.
23. W. B. Zhang, J. M. Navenot, B. Haribabu, H. Tamamura, K. Hiramatu, A. Omagari, G. Pei, J. P. Manfredi, N. Fujii, J. R. Broach, S. C. A. Peiper, J. Biol. Chem. 2002, 277, 24515-24521.
24. A. Brelot, N. Heveker, M. Montes, M. J. Alizon, J. Biol. Chem. 2000, 275, 23736-23744.
25. G. A. Donzella, D. Schols, S. W. Lin, J. A. Esté, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, J. P. Moore, Nat. Med. 1998, 4, 72-77.
26. S. Hatse, K. Princen, L.-O. Gerlach, G. Bridger, G. Henson, E. De Clercq, T. W. Schwartz, D. Schols, Mol. Pharmacol. 2001, 60, 164-173.
27. S. Hatse, K. Princen, K. Vermeire, L.-O. Gerlach, M. M. Rosenkilde, T. W. Schwartz, G. Bridger, E. De Clercq, D. Schols, FEBS Lett. 2003, 546, 300-306.
28. S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease, Gene 1989, 77, 51-59.
29. M. M. Rosenkilde, L.-O. Gerlach, J. S. Jacobsen, R. T. Skerlj, G. J. Bridger, T. W. Schwartz, J. Biol. Chem. 2004, 279, 3033-3041.
30. R. S. Y. Wong, V. Bodart, M. Metz, J. Labrecque, G. Bridger, S. P. Fricker, Mol. Pharmacol. 2008, 74, 1485-1495.
31. O. Trott, A. J. Olson, J. Comput. Chem. 2009, 31, 455-461; http://vina. scripps.edu (accessed May 11, 2010).
32. The Scripps Research Institute, MGL Tools, http://mgltools.scripps.edu (accessed May 11, 2010).
33. MOE: Molecular Operating Environment, Chemical Computing Group Inc., Montreal, QC (Canada), 2006.
34. D. A. Case, T. A. Darden, T. E. Cheatham III, C. L. Simmerling, J. Wang, R. E. Duke, R. Luo, K. M. Merz, B. Wang, D. A. Pearlman, M. Crowley, S. Brozell, V. Tsui, H. Gohlke, J. Mongan, V. Hornak, G. Cui, P. Beroza, C. Schafmeister, J. W. Caldwell, W. S. Ross, P. A. Kollman, Amber 8, University of California, San Francisco, 2004, http://amber.scripps.edu (accessed May 11, 2010).
35. A. Sali, T. L. Blundell, J. Mol. Biol. 1993, 234, 779-815.
36. R. E. Bruccoleri, Mol. Simul. 1993, 10, 151-174.
37. C. Seibert, T. P. Sakmar, Curr. Pharm. Des. 2004, 10, 2041-2062.
38. V. I. Pérez-Nueno, D. W. Ritchie, O. Rabal, R. Pascual, J. I. Borrell, J. Teixidó, J. Chem. Inf. Model. 2008, 48, 509-533.
39. J. Gasteiger, M. Marsili, Tetrahedron 1980, 36, 3219-3228.
40. C. Bissantz, G. Folkers, D. Rognan, J. Med. Chem. 2000, 43, 4759-4767.
41. H. Gutiérrez-de-Terán, M. Pastor, N. B. Centeno, J. Aqvist, F. Sanz, Chem- BioChem 2004, 5, 841-849.
42. X. Huang, J. Shen, M. Cui, L. Shen, X. Luo, K. Ling, G. Pei, H. Jiang, K. Chen, Biophys. J. 2003, 84, 171-184.
43. J. M. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollamn, D. A. Case, J. Comput. Chem. 2004, 25, 1157-1174.
44. Y. Duan, C. Wu, S. Chowdhury, M. C. Lee, G. Xiong, W. Zhang, R. Yang, P. Cieplak, R. Luo, T. Lee, J. Caldwell, J. Wang, P. Kollman, J. Comput. Chem. 2003, 24, 1999-2012.
45. R. W. Pastor, B. R. Brooks, A. Szabo, Mol. Phys. 1998, 65, 1409-1419.
46. J.-P. Ryckaert, G. Ciccotti, H. J. C. Berendsen, J. Comput. Phys. 1977, 23, 327-341.
47. G. Moncunill, M. Armand-Ugón, E. Pauls, B. Clotet, J. A. Esté, AIDS 2008, 22, 23-31.
48. G. Moncunill, M. Armand-Ugón, I. Clotet-Codina, E. Pauls, E. Ballana, A. Llano, B. Romagnoli, J. W. Vrijbloed, F. O. Gombert, B. Clotet, S. De Marco, J. A. Esté, Mol. Pharmacol. 2008, 73, 1264-1273.
49. E. Ballana, E. Pauls, J. Senserrich, B. Clotet, F. Perron-Sierra, G. C. Tucker, J. A. Esté, Blood 2009, 113, 1278-1286.
50. G. J. Bridger, R. T. Skerlj, P. E. Hernandez-Abad, D. E. Bogucki, Z. Wang, Y. Zhou, S. Nan, E. M. Boehringer, T. Wilson, J. Crawford, M. Metz, S. Hatse, K. Princen, E. De Clercq, D. Shols, J. Med. Chem. 2010, 53, 1250-1260.
51. 50 values can be used to obtain ΔG in an approximate manner, as in: R. Zhou, R. A. Friesner, A. Ghosh, R. C. Rizzo, W. L. Jorgensen, R. M. Levy, J. Phys. Chem. B 2001, 105, 10388-10397.
52. binding values with low computational cost, predicting free energy values in good qualitative agreement with experiment; see: R. Wang, Y. Lu, S. Wang, J. Med. Chem. 2003, 46, 2287-2303.
53. Approaches based on MD such as LIE (see: J. Åqvist, C. Medina, J. E. Samuelson, J. Protein Eng. 1994, 7, 385-391)
54. MM-PBSA (see: J. Srinivasan, T. E. Cheatham, P. Cieplak, P. A. Kollman, D. A. Case, J. Am. Chem. Soc. 1998, 120, 9401-9409) allow predictions that are reliable and in good agreement with experiment, but are much more computationally expensive. The results obtained using AutoDock Vina affinity scoring function are impressive due to the good agreement with experimental values obtained.